Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Return on Sales (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Return on Sales for 15 consecutive years, with 0.12% as the latest value for Q4 2025.

  • Quarterly Return on Sales fell 5.0% to 0.12% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.13% through Dec 2025, down 8.0% year-over-year, with the annual reading at 0.13% for FY2025, 8.0% down from the prior year.
  • Return on Sales hit 0.12% in Q4 2025 for Corcept Therapeutics, up from 0.09% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.34% in Q3 2022 to a low of 0.09% in Q3 2025.
  • Historically, Return on Sales has averaged 0.22% across 5 years, with a median of 0.23% in 2023.
  • Biggest five-year swings in Return on Sales: grew 7bps in 2021 and later decreased -16bps in 2022.
  • Year by year, Return on Sales stood at 0.32% in 2021, then tumbled by -50bps to 0.16% in 2022, then skyrocketed by 44bps to 0.23% in 2023, then decreased by -27bps to 0.17% in 2024, then fell by -29bps to 0.12% in 2025.
  • Business Quant data shows Return on Sales for CORT at 0.12% in Q4 2025, 0.09% in Q3 2025, and 0.18% in Q2 2025.